Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 107K | 159K | 0 | 0 | 0 |
| Gross Profit | -308K | -16K | -603K | -550K | -12K |
| Operating Income | -2M | -3M | -3M | -2M | -2M |
| EBITDA | -1M | -3M | -4M | -1M | -2M |
| Net Income | -2M | -4M | -6M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-99.96%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xebra Brands Ltd. (XBRAF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 100.0% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of -32.8%, EPS growth of +67.2%, a dividend yield of 0.0%. What stands out right now is revenue -32.8%, EPS +67.2%, free cash flow +65.4% with operating margin -1454.8% and ROIC 378.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XBRAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XBRAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XBRAF Max Drawdown
-99.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XBRAF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.8M
-49.9% YoY
Free Cash Flow
-$2.3M
-115.8% YoY
Revenue Growth
-32.8%
EPS Growth
+67.2%
Gross Margin
-288.6%
Net Margin
-1831.8%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 107K | 159K | 0 | 0 | 0 |
| Gross Profit | -308K | -16K | -603K | -550K | -12K |
| Operating Income | -2M | -3M | -3M | -2M | -2M |
| EBITDA | -1M | -3M | -4M | -1M | -2M |
| Net Income | -2M | -4M | -6M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 102K | 202K | 647K | 93K | 955K |
| Total Assets | 379K | 1M | 3M | 4M | 5M |
| Total Liabilities | 790K | 772K | 457K | 619K | 611K |
| Shareholder Equity | -155K | 796K | 3M | 3M | 5M |
| Total Debt | 0 | 0 | 29K | 67K | 321K |
| Net Debt | -102K | -202K | -618K | -26K | -634K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-115.1% YoY
Capital Expenditures
320K
-120.5% YoY
Free Cash Flow
2M
-115.8% YoY
Key ratios
Gross Margin
-288.6%
Operating Margin
-1454.8%
Net Margin
-1831.8%
ROE
-610.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.